Trial0

Clinical trial · NCT06183983 · RECRUITING · NA

Hitting the Mark: Introducing State-of-the-art MRI for Precision Radiotherapy of Glioblastoma

Sponsor: Erasmus Medical Center

We save this real registry record and notify you if its published status changes. Create an account to add profile details that improve future matching.

Summary

The goal of this prospective cohort study is to assess the potential of advanced MRI for improved radiotherapy target delineation in patients diagnosed with glioblastoma. The main questions it aims to answer are: * How does the coverage of the recurrence volume by a radiotherapy plan based on advanced MRI compare to the coverage by the clinical radiotherapy plan? * How does the distribution of the dose to organs at risk by a radiotherapy plan based on advanced MRI compare to the distribution by the clinical radiotherapy plan? Participants will undergo an extended MRI-protocol prior to radiotherapy. This extended MRI-protocol includes the clinical brain tumor imaging protocol plus additional advanced MRI-sequences. Radiation treatment and patient follow-up will occur according to the clinical standard.

Interventions

  • Extended or additional MRI-scan (with contrast) prior to radiotherapy · DIAGNOSTIC_TEST

    The MRI-protocol before radiotherapy is extended with 20 minutes. Patients who would not have received an MRI-scan prior to radiotherapy, will get an extra MRI-scan when participating.

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Written informed consent;
* Adult (18 years or older);
* Diagnosed with IDH-wildtype glioblastoma, as confirmed by pathology including molecular analysis post resection/biopsy;
* Referred to the outpatient clinic of the Dept. of Radiotherapy to undergo standard treatment with radiotherapy (30x2 Gy or 15x2.67Gy or 10x3.4Gy).

Exclusion Criteria:

* Contraindication for (3 Tesla) MRI;
* Contraindication for use of gadolinium-based contrast agent (e.g. subject having renal deficiency or known allergy);
* Referred for treatment of recurrent glioblastoma;
* Previous radiotherapy to the brain;
* Unable to give informed consent

Sites (1)

  • Erasmus Medical Center, Rotterdam, South Holland, Netherlands · RECRUITING

Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors. Registry data refreshed at most hourly; last update posted 2025-06-12.